National

The Centers for Medicare and Medicaid Services announced today that it has struck a deal with Mylan to reclassify the EpiPen, which will save the Medicaid program hundreds of millions of dollars.

Context: Part of last year's controversy over the price of EpiPens included the device's classification under the Medicaid program. It was classified as a generic rather than a brand name drug, meaning it paid less in rebates to the program.

The agreement: Mylan will reclassify the EpiPen as a brand name drug, which will recalculate the amount it pays to the program in rebates starting retroactively in April 2017.

CMS reaches EpiPen Medicaid agreement

The agreement reclassifies EpiPens, saving the government millions of dollars.

Health Care

Business

The Centers for Medicare and Medicaid Services announced today that it has struck a deal with Mylan to reclassify the EpiPen, which will save the Medicaid program hundreds of millions of dollars.Context: Part of last year&#x27;s controversy over the price of EpiPens included the device&#x27;s classification under the Medicaid program. It was classified as a generic rather than a brand name drug, meaning it paid less in rebates to the program.The agreement: Mylan will reclassify the EpiPen as a brand name drug, which will recalculate the amount it pays to the program in rebates starting retroactively in April 2017.

CMS reaches EpiPen Medicaid agreement

Go deeper